Global RNAi Drug Delivery Market 2014-2018
|出版商||TechNavio (Infiniti Research Ltd.)||商品編碼||294953|
|出版日期||內容資訊||英文 45 Pages
TechNavio's analysts forecast the Global RNAi Drug Delivery market to grow at a CAGR of 21.80 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increase in RNA therapeutic development. The Global RNAi Drug Delivery market has also been witnessing some key technological advancements. However, the targeted delivery of RNA molecules is expected to pose a challenge to the growth of this market.
TechNavio's report, the Global RNAi Drug Delivery Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global RNAi Drug Delivery market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space are Alnylam Pharmaceuticals Inc., Isis Pharmaceuticals, Inc.,Merck & Co. Inc., and Tekmira Pharmaceuticals Corp..
Other vendors mentioned in the report are Access Pharmaceuticals Inc., Calondo Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Marina Biotech Inc., PhaseRx Inc., Quark Pharmaceuticals Inc., RXi Pharmaceuticals Corp., Silence Therapeutics plc, Sirnaomics Inc., Tacere Therapeutics Inc., and Traversa Therapeutics Inc.
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.